HIV/AIDs activists protest drug price hike

Carrillo, Karen Juanita
February 2004
New York Amsterdam News;2/12/2004, Vol. 95 Issue 7, p4
The announced plans by the pharmaceutical company Abbott Laboratories Inc. to raise prices for its AIDS medicine have caused outrage among HIV/AIDS activists. In December, 2003 Abbott announced it plans to raise the price of Norvir, its famed protease inhibitor drug. Norvir, which is more commonly known as Ritonavir, was initially used in combination with other protease inhibitors as part of a drug regimen for treating HIV. But Norvir's properties were found to be too strong, yet so effective that it was soon diagnosed as an essential drug to be used in AIDS cocktails for boosting the efficiency of other HIV drugs.


Related Articles

  • Combination study of Invirase and Norvir starting.  // AIDS Patient Care & STDs;Jun96, Vol. 10 Issue 3, p187 

    Announces the clinical trial to be conducted by Hoffman-La Roche Inc. with Abbott Laboratories on the protease inhibitors Invirase in combination with Norvir and their effectiveness in the treatment of HIV/AIDS. Distinct mutation profile of Invirase.

  • Protease inhibitors raising quality-of-life issues for HIV patients. Silversides, Ann // CMAJ: Canadian Medical Association Journal;3/23/99, Vol. 160 Issue 6, p894 

    Discusses the rising concern from AIDS activists and physicians who treat HIV/AIDS patients regarding body shape and metabolic changes associated with protease inhibitors. Efforts by Dr. David Cooper to develop a consensus case definition of the condition, which is referred to as lipodystrophy;...

  • NEW DOSING OPTION.  // Drug Topics;6/6/2005, Vol. 149 Issue 11, p77 

    This article reports the potential of Abbott Laboratories Inc.'s Kaletra to be used once daily rather than twice daily in initial HIV treatment without sacrificing the efficacy of the twice-daily dosing regimen.

  • NDA for ritonavir.  // Drug Topics;2/5/96, Vol. 140 Issue 3, p28 

    Reports on the submission of a New Drug Application by Abbott Laboratories for the ritonavir protease inhibitor.

  • Heat stable Norvir tablets.  // Monthly Prescribing Reference;Mar2010, Vol. 26 Issue 3, pA19 

    The article reports on the U.S. Food and Drug Administration's (FDA) approval of a heat-stable formulation of Norvir tablets from Abbott Laboratories Inc. that can be stored at room temperature.

  • Abbott sued on ritonavir price increase. Roehr, Bob // Bay Area Reporter;6/28/2007, Vol. 37 Issue 26, p17 

    The article reports that California federal judge Claudia Wilken has authorized a class action against pharmaceutical firm Abbott Laboratories Inc. over the price increase of the anti-HIV protease inhibitor ritonavir. The lawsuit alleges a violation of antitrust laws, monopolistic practices, and...

  • Factors Associated with Poor Immunologic Responses Despite Viral Suppression in Markedly Immunosuppressed Patients. Collazos, Julio; Asensi, Víctor; Cartón, José Antonio // AIDS Patient Care & STDs;Jun2007, Vol. 21 Issue 6, p378 

    To determine the factors associated with poor immunologic responses despite viral suppression in markedly immunocompromised patients (≤200 CD4 cells per microliter at baseline), individuals with less than 100 CD4 increases after 12 months of nelfinavir-based highly active antiretroviral...

  • BITTER PILL. Roehr, Bob // Just Out;1/9/2004, Vol. 21 Issue 5, p17 

    Reports that the AIDS community is reacting with outrage and threats of boycott after Abbott Laboratories raised the price of the Norvir protease inhibitor from $1.71 to $8.57 per 100-milligram pill. Long-overdue price adjustment; Ploy by Abbott to increase the market share of the Kaletra...

  • Fosamprenavir.  // AHFS Consumer Medication Information;Jul2019, p1 

    Fosamprenavir is used with other medications to treat human immunodeficiency virus (HIV) infection in patients with or without acquired immunodeficiency syndrome (AIDS). Fosamprenavir is in a class of medications called protease inhibitors. It works by slowing the spread of HIV in the body....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics